CompletedInterventionalNot ApplicableUpdated Nov 1, 2013
Safety Study of Botulinum Toxin Type A in Post-Upper Limb Stroke Patients With Reduced Lung Function | NCT00076687 | Trialant
CompletedInterventionalPhase 2Updated Oct 3, 2011
Safety Study of Botulinum Toxin Type A in Post-Upper Limb Stroke Patients With Reduced Lung Function
ClinicalTrials.gov ID
NCT00076687
Lead Sponsor
AllerganINDUSTRY
Overall Status
Completed
Study Type
Interventional
Phase
Phase 2
Enrollment
155Actual
Last Update Posted
Oct 3, 2011Estimated
Start Date
Oct 2003
Primary Completion Date
Aug 2009Actual
Completion Date
Aug 2009Actual
Brief Summary
The purpose of this study is to evaluate the safety of injections of botulinum toxin Type A in patients with reduced lung function and focal upper limb poststroke spasticity
Stroke
Muscle Spasticity
Motor Neuron Disease
botulinum toxin Type A
saline
Ages Eligible for Study
Adult (18-64)Older Adult (65+)
Sexes Eligible for Study
All
Accepts Healthy Volunteers
No
Eligibility Criteria
Inclusion Criteria:
Abnormal pulmonary function test results;
focal, upper limb spasticity, upper motor neuron syndrome
Exclusion Criteria:
Previous exposure to botulinum toxin of any serotype